Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade C 4.33 -3.13% -0.14
AGEN closed down 3.13 percent on Friday, October 20, 2017, on 1.16 times normal volume.

Earnings due: Oct 26

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical AGEN trend table...

Date Alert Name Type % Chg
Oct 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Oct 19 50 DMA Support Bullish -3.13%
Oct 19 200 DMA Support Bullish -3.13%
Oct 19 Volume Surge Other -3.13%
Oct 19 Wide Range Bar Range Expansion -3.13%

Older signals for AGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.98
52 Week Low 3.2
Average Volume 989,468
200-Day Moving Average 3.9653
50-Day Moving Average 4.1322
20-Day Moving Average 4.557
10-Day Moving Average 4.621
Average True Range 0.2365
ADX 36.94
+DI 19.58
-DI 28.31
Chandelier Exit (Long, 3 ATRs ) 4.1605
Chandelier Exit (Short, 3 ATRs ) 4.6395
Upper Bollinger Band 4.9397
Lower Bollinger Band 4.1743
Percent B (%b) 0.2
BandWidth 16.796138
MACD Line 0.1036
MACD Signal Line 0.1511
MACD Histogram -0.0475
Fundamentals Value
Market Cap 431.75 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -3.44
Price-to-Sales 11.40
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.74
Resistance 3 (R3) 4.75 4.64 4.67
Resistance 2 (R2) 4.64 4.53 4.63 4.64
Resistance 1 (R1) 4.48 4.47 4.43 4.47 4.62
Pivot Point 4.37 4.37 4.34 4.36 4.37
Support 1 (S1) 4.21 4.26 4.16 4.20 4.04
Support 2 (S2) 4.10 4.20 4.09 4.02
Support 3 (S3) 3.94 4.10 3.99
Support 4 (S4) 3.93